Every 8-K that CURALEAF HLDGS INC (CURLF) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CURLF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CURLF filings page.
Curaleaf Holdings, Inc. (symbol: CURLF) is the issuer of record for a Form 8-K filing submitted to the SEC.
Curaleaf Holdings, Inc. (symbol: CURLF) is the issuer of record for a Form 8-K filing submitted to the SEC.
Curaleaf Holdings, Inc. (CURLF) approved compensation arrangements for Chairman and Chief Executive Officer Boris Jordan. His target 2027 short-term incentive opportunity increased from 125% to 200% of his 2027 base salary. Jordan was also awarded a discretionary target bonus of $1 million tied to strategic targets to be evaluated by the Board and Compensation Committee; the award amount is to be determined in March 2028.
Curaleaf granted Jordan 1,344,275 time-based restricted stock units with a grant date fair value of $15,448,435. They will vest in full on January 5, 2028, under the company's 2018 Stock and Incentive Plan.
Curaleaf Holdings, Inc. (CURLF) plans to report financial and operating results for the third quarter ended September 30, 2026, after market close on November 3, 2026. A conference call and audio webcast are scheduled for 5:00 p.m. ET that afternoon.
Curaleaf Holdings, Inc. (CURLF) was added to the FTSE Canada All Cap Index, effective after the close of trading on September 18, 2026. The index measures the performance of large-, mid- and small-capitalization companies listed in Canada.
This is Curaleaf’s second major Canadian benchmark inclusion, following its addition to the S&P/TSX Composite Index under the Health Care sector in September 2025.
Curaleaf Holdings, Inc. (CURLF) is pursuing a tender offer to acquire Aurora and has circulated a detailed brochure to Aurora shareholders encouraging them to tender into Curaleaf’s offer. The consideration per Aurora share is 0.3463 Curaleaf shares plus US$0.75 in cash, implying an offer price of US$4.00.
The brochure highlights that this represents a 45% premium to Aurora’s 30‑day volume weighted average price of US$2.76 as of August 10, 2026, and a 110% premium on an ex‑cash basis. Curaleaf describes the combined business as a global cannabis leader with operations in 17 countries, more than US$1.5 billion of last‑twelve‑month revenue and nearly US$350 million of adjusted EBITDA, plus at least US$40 million of expected annual cost synergies.
The materials contrast Curaleaf’s positive share performance and cash generation with Aurora’s recent declines in revenue and adjusted EBITDA and its use of equity issuance, and state that Aurora shareholders must tender their shares before December 1, 2026 if they wish to participate in the offer.
Curaleaf Holdings, Inc. (CURLF) reported that it has sent a letter to shareholders of Aurora Cannabis Inc. outlining the terms and rationale for its previously announced takeover offer. Curaleaf is offering 0.3463 Curaleaf shares plus US$0.75 in cash per Aurora share, implying a value of US$4.00 per share based on Aurora’s 30‑day VWAP of US$2.76 as of August 10, 2026, a stated 45% premium. The company highlights that, if completed, a combination of Curaleaf and Aurora would span operations in 17 countries with more than US$1.5 billion of last‑twelve‑month revenue and nearly US$350 million of adjusted EBITDA for the period ended June 30, 2026, plus at least US$40 million of expected annual cost synergies. Curaleaf’s materials state that Aurora shareholders who tender by the December 1, 2026 deadline would receive both cash and Curaleaf equity and could participate in the combined company, while Curaleaf has also scheduled a shareholder Q&A webcast for September 17, 2026.
Curaleaf Holdings, Inc. (CURLF) disclosed that on September 14, 2026 it filed an application with the Alberta Securities Commission seeking to halt share issuances under Aurora’s at-the-market share issuance program while Curaleaf’s outstanding offer to acquire all of Aurora’s shares remains in effect. Curaleaf is pursuing an expedited hearing and states that Aurora’s ATM issuances have diluted Aurora shareholders and increased the overall cost of Curaleaf’s offer.
According to Curaleaf, Aurora has issued approximately 2.81 million shares at an average price of US$3.04 since Curaleaf first expressed transaction interest, increasing the value required to complete the offer by more than US$11 million, and contributing to shareholder dilution of about 4.9% over that period and 10.8% since the ATM program began in February 2026. The company reiterates that its tender offer is governed by an Offer to Purchase and Circular dated August 18, 2026 and related U.S. and Canadian securities filings.
Curaleaf Holdings, Inc. (CURLF) reported that on September 8, 2026 it released a detailed fact sheet supporting its proposal to acquire Aurora Cannabis Inc. and responding to what it describes as misleading statements from Aurora about the offer.
Curaleaf states that its proposal represents a US$4.00 per-share offer with a 45% premium to Aurora’s prior trading price and, excluding Aurora’s cash, a 110% premium. Curaleaf indicates that about 19% of the offer value is in cash and the rest in Curaleaf shares, with an additional US$5.00 cap structure that it says equates to a premium within the 92nd percentile of Canadian M&A premiums over the past decade. Curaleaf contrasts its own cumulative $447 million of positive operating cash flow since fiscal 2021 with what it describes as more than C$480 million of negative operating cash flow at Aurora since FY21A and over C$5 billion of impairments, all based on Aurora’s public disclosures.
Curaleaf further highlights its scale and ownership structure, saying its market capitalization was more than 13 times Aurora’s before the offer, that insiders hold roughly 20% of Curaleaf (about US$500 million invested) versus roughly 1% insider ownership at Aurora, and that approximately 60% of Curaleaf’s business is U.S. medical cannabis. The communication emphasizes expected benefits from possible U.S. federal cannabis reform and reiterates that many of the statements are forward-looking and subject to risks described in Curaleaf’s Canadian securities filings.
Curaleaf Holdings, Inc. (CURLF) reports, via a current report and press release, on its contested offer for Aurora Cannabis and reiterates its view that the proposal is attractive for Aurora shareholders. Curaleaf highlights that its offer represents a 45% premium to Aurora’s unaffected trading price and notes a US$5.00 share-price cap that it says equals an 82% premium to Aurora’s 30‑day VWAP on August 10, 2026. Curaleaf also cites implied valuation metrics it believes are favorable versus Canadian cannabis peers.
Curaleaf presents operating and balance sheet data to support its position, stating that it generated US$145 million of operating cash flow over the last twelve months ended June 30, 2026, including US$50 million of operating cash flow and US$17 million of free cash flow in the first half of 2026 while investing US$33 million in growth. It reports raising US$500 million of senior secured notes and describes net debt (excluding uncertain tax positions) as about 25% of total capitalization versus a cited peer average of 37%. Curaleaf further notes an uncertain tax position related to Section 280E equal to 13% of total enterprise value, which it compares to an approximate 30% peer average, and states that federal rescheduling of medical cannabis has removed future 280E accruals.
Curaleaf Holdings, Inc. (CURLF) reported that it issued a press release on August 24, 2026 responding to recent public statements by Aurora Cannabis about Curaleaf’s outstanding offer for Aurora. Curaleaf reiterates that its proposal provides Aurora shareholders with a “substantial premium” and the ability to participate in what it describes as a larger, stronger global cannabis platform.
Curaleaf states that there has been no substantive negotiation with Aurora, noting that Aurora has not signed an NDA, held deal-focused discussions, or permitted a site visit, while Curaleaf maintains it remains willing to meet at any time to discuss a transaction. Curaleaf’s commentary on Aurora’s business performance, including revenue, EBITDA, cash flow and cultivation yield figures, is based on Aurora’s publicly disclosed information and is presented as Curaleaf’s analysis of Aurora’s results and guidance. Curaleaf also highlights that Aurora’s share price rose and has traded near the implied value of Curaleaf’s proposal after the offer announcement, which Curaleaf characterizes as market recognition of the strategic rationale of the transaction. The press release is furnished as Exhibit 99.1 and is not deemed filed for Exchange Act liability purposes.
Curaleaf Holdings, Inc. has formally launched a take-over bid to acquire all issued and outstanding common shares of Aurora Cannabis Inc. Aurora shareholders would receive total implied consideration of US$4.00 per share, consisting of 0.3463 Curaleaf subordinate voting share plus US$0.75 in cash per Aurora share, based on Curaleaf’s US$9.39 closing price on August 10, 2026. This represents a 45% premium to Aurora’s 30‑day VWAP unaffected share price of US$2.75, and a stated 110% ex‑cash premium.
The offer includes a maximum value per Aurora share of US$5.00, with the share component adjustable based on Curaleaf’s 20‑day VWAP at closing. It is not subject to financing or due‑diligence conditions and remains open until 5:00 p.m. Mountain Time on December 1, 2026, subject to extensions. Conditions include minimum tender thresholds, required regulatory approvals, absence of a material adverse effect, and effectiveness of a U.S. registration statement.
Curaleaf presents strategic reasons for the transaction, highlighting an expected combined business with more than US$1.5 billion of last‑twelve‑month revenue, nearly US$350 million of adjusted EBITDA, and at least US$40 million of targeted annual cost synergies, along with expanded global scale and access to the U.S. cannabis market.
Curaleaf Holdings, Inc. announced its intention to launch a take-over bid for Aurora Cannabis Inc., offering total implied consideration of US$4.00 per Aurora share. Each share would receive 0.3463 Curaleaf subordinate voting shares plus US$0.75 in cash, representing a 45% premium to Aurora’s 30-day VWAP of US$2.75 and a 110% premium to the 30-day VWAP excluding Aurora’s balance sheet cash.
The implied value is capped at US$5.00 per share (based on the 20-day VWAP of Curaleaf shares); if Curaleaf’s share price rises substantially before take-up, the share component would be adjusted so that total consideration equals the Cap Price. Curaleaf highlights a potential combined business with more than US$1.5 billion of last-twelve-months revenue, nearly US$350 million of LTM Adjusted EBITDA, and a pro forma market capitalization approaching US$3.0 billion, as well as at least US$40 million of expected annual cost synergies.
The company emphasizes strategic benefits including broader international footprint, vertical integration, and immediate exposure for Aurora shareholders to the roughly US$32 billion U.S. legal cannabis market. Curaleaf has not yet formally commenced the offer, which is expected to remain open for 105 days once launched and will not be subject to due diligence or financing conditions; Curaleaf also notes there is no assurance the offer will ultimately be made or on these terms.
Curaleaf Holdings, Inc. will voluntarily comply with U.S. domestic issuer reporting requirements, rather than those for foreign private issuers. To support this transition it prepared a Form 10‑K for the year ended December 31, 2025 and a Form 10‑Q for the quarter ended March 31, 2026, and is concurrently filing a Form 10‑Q for the quarter ended June 30, 2026.
The 2025 10‑K describes a vertically integrated, global cannabis operator with 168 owned and managed U.S. retail locations in 14 states and more than 1,300 wholesale accounts as of December 31, 2025, expanding to 176 locations by August 5, 2026. Cultivation infrastructure includes 17 sites with about 1.5 million square feet of capacity and EU‑GMP certified production supporting distribution in 15 countries.
For 2025, domestic revenue was $1,095.7 million and international revenue was $172.5 million, with 85% of total revenue derived from U.S. cannabis activities. The company reports 5,554 employees worldwide and highlights extensive regulatory, tax, banking and capital‑markets risks tied to cannabis remaining illegal under U.S. federal law.
Curaleaf Holdings, Inc. reported second quarter 2026 net revenue of $340.1 million, a 10% increase from $310.6 million a year earlier, with domestic revenue of $288.7 million and international revenue of $51.4 million. Retail and wholesale revenues were $336.7 million and management fee income was $3.4 million.
Gross profit was $169.9 million for a 50% margin. Net income from continuing operations attributable to Curaleaf was $12.5 million, or $0.05 per basic share. Adjusted EBITDA was $70.1 million with a 20.6% margin. For the first six months of 2026, net revenue was $664.3 million, gross profit was $327.2 million, net income from continuing operations was $82.6 million, or $0.32 per basic share, and adjusted EBITDA was $133.5 million with a 20.1% margin.
As of June 30, 2026, Curaleaf held $107.0 million in cash and cash equivalents and had $611.5 million of outstanding debt, net. The company invested $32.9 million in capital expenditures, repurchased 1.01 million shares for $7.4 million, expanded its U.S. retail footprint toward 176 dispensaries, and completed the buyout of the remaining 45% equity interest in Four20 Pharma in Germany.